A Phase 1, Open-label, Single-center Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Jul 2017
Price : $35 *
At a glance
- Drugs Iberdomide (Primary)
- Indications Multiple myeloma; Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 30 Jun 2017 Status changed from active, no longer recruiting to completed.
- 20 Jun 2017 Planned End Date changed from 13 Jun 2017 to 30 Jun 2017.
- 20 Jun 2017 Planned primary completion date changed from 13 Jun 2017 to 30 Jun 2017.